Table 4 Impact of American College of Rheumatology (ACR) and disease remission status on stopping work*
Hazard ratio (95% CI)
For stopping work based on achieving ACR outcomesFor adalimumab patientsFor DMARD patients
ACR outcome achieved at 6 months
    ACR20 (n = 67 adalimumab, n = 130 comparison)0.555 (0.457 to 0.674)1.011 (0.722 to 1.417)0.476 (0.375 to 0.604)
    ACR50 (n = 44 adalimumab, n = 28 comparison)0.685 (0.506 to 0.929)0.894 (0.523 to 1.526)0.619 (0.428 to 0.896)
    ACR70 (n = 5 adalimumab, n = 12 comparison)0.628 (0.344 to 1.147)0.447 (0.061 to 3.253)0.647 (0.343 to 1.220)
ACR outcome achieved at 12 months
    ACR20 (n = 91 adalimumab, n = 91 comparison)0.603 (0.493 to 0.737)0.993 (0.727 to 1.356)0.481 (0.367 to 0.630)
    ACR50 (n = 36 adalimumab, n = 37 comparison)0.639 (0.474 to 0.862)0.985 (0.619 to 1.568)0.539 (0.364 to 0.798)
    ACR70 (n = 9 adalimumab, n = 12 comparison)0.521 (0.291 to 0.931)0.793 (0.195 to 3.226)0.530 (0.279 to 1.004)
ACR outcome achieved at 24 months
    ACR20 (n = 105 adalimumab, n = 62 comparison)0.514 (0.418 to 0.633)1.011 (0.753 to 1.359)0.345 (0.251 to 0.475)
    ACR50 (n = 50 adalimumab, n = 25 comparison)0.572 (0.422 to 0.776)1.050 (0.695 to 1.588)0.395 (0.247 to 0.632)
    ACR70 (n = 20 adalimumab, n = 10 comparison)0.588 (0.367 to 0.943)1.052 (0.579 to 1.912)0.351 (0.155 to 0.795)
Impacts based on DAS28 scores
    EULAR response (n = 97 adalimumab, n = 118 comparison)0.572 (0.475 to 0.688)1.001 (0.753 to 1.331)0.452 (0.354 to 0.578)
    Disease remission (n = 165 adalimumab, n = 85 comparison)0.669 (0.551 to 0.812)1.007 (0.753 to 1.345)0.524 (0.391 to 0.702)
  • *From proportional hazards regressions controlling for time to event (stopping work), duration of study enrolment, treatment type (adalimumab vs disease-modifying antirheumatic drugs), percentage working at baseline, and baseline age, erythrocyte sedimentation rate, C-reactive protein, number of swollen and tender joints, 28-joint Disease Activity Score, and joint pain, patient-rated global and physician-rated global assessment visual analogue scale scores.

  • EULAR, European League Against Rheumatism.